Although historically the intra-aortic balloon pump has been the only mechanical circulatory support device available to clinicians, a number of new devices have become commercially available and have entered clinical practice. These include axial flow pumps, such as Impella â ; left atrial to femoral artery bypass pumps, specifically the TandemHeart; and new devices for institution of extracorporeal membrane oxygenation. These devices differ significantly in their hemodynamic effects, insertion, monitoring, and clinical applicability. This document reviews the physiologic impact on the circulation of these devices and their use in specific clinical situations. These situations include patients undergoing high-risk percutaneous coronary intervention, those presenting with cardiogenic shock, and acute decompensated heart failure. Specialized uses for right-sided support and in pediatric populations are discussed and the clinical utility of mechanical circulatory support devices is reviewed, as are
INTRODUCTION
Percutaneous hemodynamic support has historically been limited to the intra-aortic balloon pump (IABP) or extracorporeal bypass with membrane oxygenator (ECMO) (1) (2) (3) . Although the IABP is widely available, limitations include modest hemodynamic support or myocardial protection; ECMO can provide full hemodynamic support but is limited by complexity and need for perfusion expertise and is rarely used in the catheterization laboratory environment. These limitations have spurred development of alternative percutaneous mechanical circulatory support (MCS) devices with the potential to provide greater cardiac and systemic support and reduce morbidity and mortality among high-risk patient subsets (1) .
In parallel, cardiovascular practice has seen rapid growth in cohorts that may benefit from the use of such devices (4) . These include patients with chronic systolic dysfunction and acute decompensated heart failure (ADHF), those in whom high-risk multivessel percuta- 
CLINICAL SETTINGS AND HEMODYNAMIC SUBSTRATES
Potential benefits of MCS include the ability to: 1) maintain vital organ perfusion, thereby preventing systemic shock syndrome, 2) reduce intracardiac filling pressures, thereby reducing congestion and/or pulmonary edema, 3) reduce left ventricular volumes, wall stress, and myocardial oxygen consumption, 4) augment coronary perfusion, 5) support the circulation during complex interventional and electrophysiologic procedures, and, theoretically, 6) limit infarct size. As new MCS devices become available, several specific patient populations likely to benefit from this therapy can be identified. These include patients undergoing high-risk PCI (HR-PCI), and those with large acute myocardial infarctions (AMI), acute decompensated heart failure (ADHF), and cardiogenic shock. Patient-specific variables include increased age, impaired left ventricular function, symptoms of heart failure, diabetes mellitus, chronic kidney disease, prior myocardial infarction, multivessel or left main disease, and peripheral arterial disease (11) (12) (13) (14) (15) (16) (17) (18) . Lesion-specific variables encompass anatomic characteristics such as left main stenosis, bifurcation disease, saphenous vein grafts, ostial stenoses, heavily calcified lesions, and chronic total occlusions (19) (20) (21) (22) (23) . Lesions that supply a large territory (including a last patent conduit, left main disease, or critical 3-vessel disease) also increase risk should dissection or occlusion occur during PCIparticularly in combination with poor ventricular function. Finally, the clinical setting, such as acute coronary syndrome or cardiogenic shock, can increase the risk of an adverse event with PCI. The combination of severe left ventricular dysfunction, particularly ADHF, with a lesion(s) that is difficult to treat is an example of HR-PCI.
Need for an MCS device for HR-PCI depends upon the hemodynamic condition of the patient at the time of PCI, the anticipated risk of hemodynamic compromise during the procedure, and the need for hemodynamic support after revascularization. Risk calculators specifically designed to assess the real-time need for MCS during PCI do not exist and require further investigation.
Acute Myocardial Infarction
Although the vast majority of non-ST-and ST-segment elevation myocardial infarction (NSTEMI and STEMI) patients can be safely and effectively treated using standard techniques, selected patients may benefit from the unloading and hemodynamic effects of MCS, which may serve to reduce myocardial oxygen consumption and ischemia, and improve coronary perfusion through effects on coronary blood flow. Due to the presence of active and ongoing myocardial ischemia, NSTEMI and STEMI are among the high-risk clinical scenarios for PCI. Several factors make these patients high risk. Due to myocardial ischemia, left ventricular (LV) diastolic and systolic function is impaired and contributes to elevated in-tracardiac filling pressures. Furthermore, PCI is associated with the risk of thrombotic embolization and infarct extension, which can lead to hemodynamic decompensation. Finally, although standard therapy for STEMI is rapid myocardial reperfusion, up to one-third of STEMI patients do not experience effective reperfusion as assessed by resolution of ST-segment elevation, and reperfusion itself may cause myocardial damage (reperfusion injury) and life-threatening ventricular arrhythmias (24) . Whether MCS can reduce myocardial injury in the setting of acute occlusion and subsequent reperfusion for myocardial infarction is unknown.
Advanced Heart Failure and Cardiogenic Shock
Heart failure is a major cause of morbidity and mortality worldwide. In the United States alone, an estimated 5.7 million adults 20 years or older have heart failure, of whom nearly 50% have reduced LV ejection fraction (25) . Each pressure volume (PV) loop represents one cardiac cycle (A). Beginning at the end of isovolumic relaxation (Point 1), LV volume increases during diastole (Phase 1 to 2). At end-diastole (Point 2), LV volume is maximal and isovolumic contraction (Phase 2 to 3) begins. At the peak of isovolume contraction, LV pressure exceeds aortic pressure and blood begins to eject from the LV into the aorta (Point 3). During this systolic ejection phase, LV volume decreases until aortic pressure exceeds LV pressure and the aortic valve closes, which is known as the end-systolic pressure-volume point (ESPV) (Point 4). Stroke volume (SV) is represented by the width of the PV loop as the volume difference between end-systolic and end-diastolic volumes (Points 1 and 2). The shaded area within the loop represents stroke work. Load-independent LV contractility, also known as E max , is defined as the maximal slope of the ESPV point under various loading conditions, known as the ESPV relationship (ESPVR). Effective arterial elastance (E a ) is a component of LV after-load and is defined as the ratio of end-systolic pressure and stroke volume. Under steady state conditions, optimal LV pump efficiency occurs when the ratio of E a :E max approaches 1.
(B) Representative PV loop in AMI (blue loop). LV contractility (E max ) is reduced; LV pressure, SV, and LV stroke work may be unchanged or reduced; and LVEDP is increased. (C) Representative PV loop in cardiogenic shock (gray loop). E max is severely reduced; LVEDV and LVEDP are increased; and SV is reduced. Further device iterations may allow broader application.
AVAILABLE DEVICES AND/OR STRATEGIES

Intra-Aortic Balloon Pump
The IABP remains the most commonly used form of cir- 
Hemodynamic Effects
The IABP increases diastolic blood pressure, decreases afterload, decreases myocardial oxygen consumption, increases coronary artery perfusion, and modestly enhances cardiac output. The IABP provides modest ventricular unloading but does increase mean arterial pressure and coronary blood flow. Patients must have some level of left ventricular function and electrical stability for an IABP to be effective, as any increase in cardiac output is dependent on the work of the heart itself.
Optimal hemodynamic effect from the IABP is dependent on several factors, including the balloon's position in the aorta, the blood displacement volume, the balloon diameter in relation to aortic diameter, the timing of balloon inflation in diastole and deflation in systole, and the patient's own heart rate, blood pressure and vascular resistance (44) .
Contraindications and Complications
Aortic valve regurgitation of greater than a mild degree 
Adequate RV function or a concomitant RVAD is usually 
LV to Aorta-Assist Devices
The Impella is a nonpulsatile axial flow Archimedes-screw pump designed to propel blood from the LV into the 
Hemodynamic Effects
The Impella pumps blood from the LV into the ascending aorta, thereby unloading the LV and increasing forward 
Contraindications and Complications
Use of the Impella is contraindicated in patients with a mechanical aortic valve or left ventricular thrombus. 
Hemodynamic Effects
V-V ECMO offers gas exchange without hemodynamic support and is useful for conditions associated with severe impairment of gas exchange with stable hemodynamics such as ARDS, or rarely, pulmonary embolism. armamentarium of mechanical therapies for heart failure will evolve and will require algorithms for risk stratification, patient and device monitoring, and weaning protocols.
Theoretical Comparison of Hemodynamic and Myocardial Effects
The primary mechanism of benefit of MCS is to reduce native LV stroke work and myocardial oxygen demand while maintaining systemic and coronary perfusion.
Myocardial effects of reducing LV volume and pressure, known as "LV unloading" have been well described (76) . 
Intra-Aortic Balloon Pump
In a retrospective study of 48 patients who underwent primary PCI for acute myocardial infarction complicated by cardiogenic shock, those that had an IABP placed before PCI had a lower peak creatine kinase (CK), lower in-hospital mortality and fewer major adverse cardiac events than those with IABP inserted after PCI (82).
However, a nonrandomized study examined the use of IABP in HR-PCI using the National Cardiovascular Data Registry database and found no differences in overall mortality and wide regional variation in the use of IABP in this setting (83) . Similarly, a meta-analysis of IABP use in AMI found no benefit and potential harm, including a higher risk of stroke (46) . Finally, prospective 
Percutaneous Mechanical Circulatory Support
The opportunity for these systems to provide greater hemodynamic support than IABP has been demonstrated system has been demonstrated to be safe in HR-PCI (92) although an earlier study raised some concerns about hemolysis and increased left ventricular volume after device activation (93) .
A large observational study of the Impella 2.5 device in HR-PCI has been published (94) . Most patients were extremely high risk, including inoperable patients with a high prevalence of chronic kidney disease, prior coronary artery bypass grafting, and severe LV dysfunction, as well as a high prevalence of NYHA class III to IV heart failure. Despite these risk factors, procedural success was high with a 90% success rate with multi-vessel revascularization and 8% rate of 30-day major adverse cardiac events. Survival was 91% and 88% at 6 and 12 months, In patients undergoing HR-PCI, more data are needed on subgroups of patients that may benefit from support (e.g., based on clinical or angiographic characteristics).
Likewise, for patients with AMI complicated by cardiogenic shock, the limitations of IABP use are apparent.
A phase III, multicenter, three-arm study comparing outcomes with IABP, MCS or neither, with power to Complications of AMI Ischemic mitral regurgitation is particularly well-suited to these devices as the hemodynamic disturbance is usually acute and substantial. Acutely depressed LV function from large AMI during and after primary PCI is an increasing indication for temporary MCS use. Cardiogenic shock from RV infarction can be treated with percutaneous right ventricular support.
Severe heart failure in the setting of nonischemic cardiomyopathy
Examples include severe exacerbations of chronic systolic heart failure as well as acutely reversible cardiomyopathies such as fulminant myocarditis, stress cardiomyopathy, or peripartum cardiomyopathy. In patients presenting in INTERMACS profiles 1 or 2, MCS can be used as a bridge to destination VAD placement or as a bridge to recovery if the ejection fraction rapidly improves (108) .
Acute cardiac allograft failure Primary allograft failure (adult or pediatric) may be due to acute cellular or antibody-mediated rejection, prolonged ischemic time, or inadequate organ preservation.
Post-transplant RV failure Acute RV failure has several potential causes, including recipient pulmonary hypertension, intraoperative injury/ ischemia, and excess volume/blood product resuscitation. MCS support provides time for the donor right ventricle to recover function, often with the assistance of inotropic and pulmonary vasodilator therapy (109) .
Patients slow to wean from cardiopulmonary bypass following heart surgery Although selected patients may be transitioned to a percutaneous system for additional weaning, this is rarely done.
Refractory arrhythmias
Patients can be treated with a percutaneous system that is somewhat independent of the cardiac rhythm. For recurrent, refractory, ventricular arrhythmias, ECMO may be required for biventricular failure.
Prophylactic use for high risk PCI Particularly in patients with severe LV dysfunction (EF <20% to 30%) and complex coronary artery disease involving a large territory (sole-remaining vessel, left main or three vessel disease) (94, 95, 98 The potential advantages of these devices over pharmacologic therapy such as inotropes, with known adverse effects on myocardial oxygen consumption and cardiac rhythm, need to be determined in controlled studies.
Finally, more development and clinical data are needed on RV support devices.
Cost Effectiveness
The support devices discussed in this document are and $144,257, respectively, p < 0.001) (114).
Future Directions: Myocyte Protection and Recovery
Another potential use of ventricular support is myocyte preservation during acute ischemic insult (115) . Ventricular unloading may reduce myocardial infarct size through enhanced hemodynamics, preserved energetics, and activation of cardioprotective mechanisms (48, 116) .
Despite limited unloading potency, some animal infarct model studies found improved myocyte recovery with IABP use (117, 118) . However, as described above, the CRISP-AMI study (101) 
CONCLUSIONS AND SUMMARY
The availability of percutaneous MCS has broadened therapeutic options for patients that require hemodynamic support. A variety of devices are now available, each with specific technical and clinical nuances.
Unfortunately, definitive clinical evidence is in many cases either unavailable or controversial. We provide the following consensus-based summary statements based upon the anticipated hemodynamic effects and risks, clinical outcomes data as well as knowledge gaps.
1. Percutaneous MCS provides superior hemodynamic support compared to pharmacologic therapy. This is particularly apparent for the Impella and TandemHeart devices. These devices should remain available clinically and be appropriately reimbursed. Percutaneous MCS Devices in Cardiovascular Care e19 pumps including the Impella CP and TandemHeart.
ECMO may also provide benefit, particularly for patients with impaired respiratory gas exchange. Further data are necessary.
